Clinical Study to Compare Visual Performance of Two Trifocal IOLs (PHY1702)

May 5, 2021 updated by: Beaver-Visitec International, Inc.

Clinical Study to Compare Visual Performance of Two Trifocal IOLs With Different Material (Hydrophobic and Hydrophilic)

Prospective, randomised, controlled, single-surgeon, single-center post-market clinical follow up study to compare the clinical outcomes of two trifocal IOLs with different material

Study Overview

Detailed Description

This is a prospective, randomised, controlled, single-surgeon, single-center post-market clinical follow up study whereby patients undergoing routine cataract surgery will have bilateral implantation of trifocal intraocular lenses. The patients will either be implanted with the hydrophobic IOL FineVision POD F GF or the hydrophilic IOL FineVision Pod F.

The primary and secondary effectiveness data for visual acuity, contrast sensitivity, halometry, aberrometry, questionnaire outcomes and any adverse events will be collected.

Subjects participating in the trial will attend a total of 10 study visits (1 preoperative, 2 operative and 7 postoperative) over a period of 3 months. Subjects would have the option for unscheduled visits if required medically.

Primary endpoint data will be collected at the 3 months follow up visit. Data analyses will be done after the last patient finished the final examination to support the study publication plan.

Study Type

Interventional

Enrollment (Actual)

53

Phase

  • Not Applicable

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

      • Madrid, Spain, 28003
        • Innova Ocular IOA Madrid

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

50 years and older (ADULT, OLDER_ADULT)

Accepts Healthy Volunteers

Yes

Genders Eligible for Study

All

Description

Inclusion Criteria:

  • Cataractous eyes with no comorbidity
  • Spontaneously emitting the desire for spectacle independence after surgery and with realistic expectation.
  • Availability, willingness and sufficient cognitive awareness to comply with examination procedures
  • Signed informed consent

Exclusion Criteria:

  • Irregular astigmatism
  • Age of patient < 50 years
  • Regular corneal astigmatism >1.00 dioptres by an automatic keratometer or biometer or >1.25 dioptres if the steep axis of cylinder is between 90° and 120° in one or both eyes
  • Difficulty for cooperation (distance from their home, general health condition)
  • Acute or chronic disease or illness that would increase risk or confound study results (e.g. diabetes mellitus (with retinopathy), immunocompromised, glaucoma etc…)
  • Any ocular comorbidity
  • History of ocular trauma or prior ocular surgery including refractive procedures
  • Capsule or zonular abnormalities that may affect postoperative centration or tilt of the lens (e.g. pseudoexfoliation syndrome, chronic Uveitis, Marfan's syndrome)
  • Pupil abnormalities (non-reactive, tonic pupils, abnormally shaped pupils or pupils that do not dilate under mesopic/scotopic conditions)
  • AMD suspicious eyes (determined by OCT)
  • Complicated surgery

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: TREATMENT
  • Allocation: RANDOMIZED
  • Interventional Model: PARALLEL
  • Masking: NONE

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
EXPERIMENTAL: IOL implantation experimental
hydrophobic, trifocal intraocular lens POD F GF
Implantation of trifocal IOL POD F GF consisting of hydrophobic material
ACTIVE_COMPARATOR: IOL implantation active comparator
hydrophilic, trifocal intraocular lens POD F
Implantation of trifocal IOL POD F consisting of hydrophilic material

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
monocular Uncorrected Distance Visual Acuity (UDVA) under photopic light conditions.
Time Frame: 3 months postoperative
The primary study end point is to show statistically equal visual acuity outcomes between both study groups. The primary study endpoint parameter is monocular Uncorrected Distance Visual Acuity (UDVA) under photopic light conditions. UDVA is measured with ETDRS charts placed in 4m distance according to ISO 11979-7:2014
3 months postoperative

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Manifested refraction - Sphere
Time Frame: 3 months postoperative
The spherical part of the manifested refraction is measured by means of a phoropter. The examination is done according to ISO 11979-7:2014.
3 months postoperative
Manifested refraction - Cylinder
Time Frame: 3 months postoperative
The cylindrical part of the manifested refraction is measured by means of a phoropter. Amount of cylinder and cylinder axis will be noted. The examination is done according to ISO 11979-7:2014. This data will also be used to calculate the manifested refractive spherical equivalent (MRSE)
3 months postoperative
Uncorrected Distance Visual Acuity (UDVA)
Time Frame: 3 months postoperative
UDVA is measured with ETDRS charts placed in 4m distance according to ISO 11979-7:2014. This assessment is done binocularly.
3 months postoperative
Corrected Distance Visual Acuity (CDVA)
Time Frame: 3 months postoperative
CDVA is measured with ETDRS charts placed in 4m distance with best aided corrective glasses according to ISO 11979-7:2014. This assessment is done monocularly and binocularly.
3 months postoperative
Distance Corrected Intermediate Visual Acuity at 80cm (DCIVA)
Time Frame: 3 months postoperative
DCIVA is measured with Radner reading charts placed in 80cm distance with corrective glasses for far distance according to ISO 11979-7:2014. This assessment is done monocularly and binocularly.
3 months postoperative
Distance Corrected Intermediate Visual Acuity at 63cm (DCIVA)
Time Frame: 3 months postoperative
DCIVA is measured with ETDRS charts placed in 63cm distance with corrective glasses for far distance according to ISO 11979-7:2014. This assessment is done monocularly and binocularly.
3 months postoperative
Distance Corrected Near Visual Acuity at 40cm (DCNVA)
Time Frame: 3 months postoperative
DCNVA is measured with Radner reading charts placed in 40cm distance with corrective glasses for far distance according to ISO 11979-7:2014. This assessment is done monocularly and binocularly.
3 months postoperative
Distance Corrected Near Visual Acuity at 25cm (DCNVA)
Time Frame: 3 months postoperative
DCNVA is measured with Radner reading charts placed in 25cm distance with corrective glasses for far distance according to ISO 11979-7:2014. This assessment is done monocularly and binocularly.
3 months postoperative
Halometry
Time Frame: 3 months postoperative
Halometry outcomes, measurement by halos software v1.0
3 months postoperative
Contrast Sensitivity
Time Frame: 3 months postoperative
Contrast Sensitivity under photopic and mesopic light conditions using the standardized contrast sensitivity device CSV-1000 (VectorVision)
3 months postoperative
Aberrometry - SA
Time Frame: 3 months postoperative
Aberrometry outcomes are measured with a standard aberrometer. In this examination, the following values will be evaluated: Spherical aberration
3 months postoperative
Aberrometry - HOA
Time Frame: 3 months postoperative
Aberrometry outcomes are measured with a standard aberrometer. In this examination, the following values will be evaluated: High Order Aberrations
3 months postoperative
Aberrometry - Tilt
Time Frame: 3 months postoperative
Aberrometry outcomes are measured with a standard aberrometer. In this examination, the following values will be evaluated: lens tilt
3 months postoperative
OQAS II - OSI
Time Frame: 3 months postoperative
Outcomes of OQAS II diagnostic device (Ocular Scatter Index)
3 months postoperative
OQAS II - MTF
Time Frame: 3 months postoperative
Outcomes of OQAS II diagnostic device (Modular Transfer Function)
3 months postoperative
OQAS II - Strehl Ratio
Time Frame: 3 months postoperative
Outcomes of OQAS II diagnostic device (Strehl Ratio)
3 months postoperative
questionnaire
Time Frame: 3 months postoperative
Outcomes measures of a questionnaire to address the general patient satisfaction and possible side effects of the treatment. For this study, the validated and verified questionnaire VFQ-25 (National Eye Institute) will be used. The maximum score for each question is 100. The scoring and evaluation of the questionnaire will be done according to the official guidelines and manual provided by National Eye Institute
3 months postoperative

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Investigators

  • Principal Investigator: Francisco Poyales Galan, MD, Innova Ocular IOA Madrid

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (ACTUAL)

October 2, 2017

Primary Completion (ACTUAL)

May 21, 2019

Study Completion (ACTUAL)

May 21, 2019

Study Registration Dates

First Submitted

September 26, 2017

First Submitted That Met QC Criteria

November 15, 2017

First Posted (ACTUAL)

November 20, 2017

Study Record Updates

Last Update Posted (ACTUAL)

May 6, 2021

Last Update Submitted That Met QC Criteria

May 5, 2021

Last Verified

May 1, 2021

More Information

Terms related to this study

Other Study ID Numbers

  • PHY1702

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

NO

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Cataract

Clinical Trials on IOL implantation experimental

3
Subscribe